In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...
GlobalData on MSN2d
OSE’s UC therapy prompts 16% clinical remission after ten weeksThe CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.
Lusvertikimab achieved statistical significance on the primary and secondary endpoints in moderate to severe active ulcerative colitis (UC) patients during the 10-week induction period of ...
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...
Pr. Walter Reinisch, Director of the IBD Study Group at the Medical University of Vienna, Department of Internal Medicine, Vienna, Austria, commented: “Lusvertikimab has been shown to significantly ...
Using Cellectis' TALEN ® gene editing technology, we developed 'Smart CAR T cells' with the ability to express a ...
"The companies selected for our Sales Training and Enablement Watchlist are making a significant impact with innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback